The rapid development of the industry continues, following the trend mentioned in our previous report about Q2 2019. Now not only are private investors getting interested in AI for Drug Discovery companies, but the Biopharmaceutical companies are looking for cooperation with AI startups on their own. In Q3 2019 460 investors were identified. Companies, Corporations, and R&D Centers demonstrated a growing interest in the industry as well. The report also highlights 30 Pharma corporations applying AI for drug discovery and 25 Tech corporations and 15 Chemical Corporations applying advanced AI applications in healthcare.
This 145-page “AI for Drug Discovery, Biomarker Development and Advanced R&D Landscape Overview 2019 / Q3” report marks the eighth installment in Deep Knowledge Analytics Pharma Division’s landmark series of reports on the topic of Artificial Intelligence in Drug Discovery, first begun in 2017. These reports are released on a quarterly basis, and are designed to provide an overview of the industry landscape, to reveal trends and correlations, and to benchmark the performance of key industry players and participants.